Barclays Has Lowered Expectations for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE) had its price target decreased by stock analysts at Barclays from $23.00 to $21.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s target price points to a potential downside of 0.50% from the company’s previous close.

Several other analysts have also weighed in on KVUE. Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Jefferies Financial Group began coverage on Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective for the company. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Finally, Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and upped their target price for the company from $21.00 to $26.00 in a report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $23.08.

Kenvue Trading Down 0.4 %

NYSE:KVUE opened at $21.11 on Friday. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a market cap of $40.46 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 1.99 and a beta of 1.46. The business has a fifty day moving average of $22.42 and a 200-day moving average of $21.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.31 earnings per share. Equities analysts predict that Kenvue will post 1.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KVUE. Mutual of America Capital Management LLC raised its position in Kenvue by 40.4% during the second quarter. Mutual of America Capital Management LLC now owns 317,504 shares of the company’s stock valued at $5,772,000 after buying an additional 91,398 shares during the period. Meiji Yasuda Asset Management Co Ltd. increased its position in Kenvue by 19.3% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 64,465 shares of the company’s stock worth $1,172,000 after purchasing an additional 10,425 shares during the last quarter. Amalgamated Bank increased its position in Kenvue by 6.2% in the 2nd quarter. Amalgamated Bank now owns 386,739 shares of the company’s stock worth $7,031,000 after purchasing an additional 22,605 shares during the last quarter. Elo Mutual Pension Insurance Co increased its position in Kenvue by 13.0% in the 2nd quarter. Elo Mutual Pension Insurance Co now owns 161,275 shares of the company’s stock worth $2,932,000 after purchasing an additional 18,498 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Kenvue in the 2nd quarter worth about $746,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.